Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
BVS
BVS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
BVS News
Wall Street Analysts Adjust Ratings on Key Stocks
Feb 09 2026
Benzinga
BIOVENTUS INC: BARRINGTON RESEARCH STARTS COVERAGE WITH OUTPERFORM RATING AND SETS PRICE TARGET AT $13
Feb 09 2026
moomoo
Bravura Solutions Projects FY2026 Revenue of A$265-275 Million Amid Insider Buying
Jan 01 2026
Yahoo Finance
BioVersys Initiates BV100 Phase 3 Clinical Trial, Raises CHF 76.7 Million in IPO
Dec 11 2025
Globenewswire
Halper Sadeh Investigates Bioventus for Potential Shareholder Compensation
Dec 05 2025
PRnewswire
Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products
Jul 30 2025
Newsfilter
Cantor Fitzgerald Initiates Coverage On Bioventus with Overweight Rating, Announces Price Target of $12
Jul 07 2025
Benzinga
Peek Under The Hood: FHLC Has 21% Upside
Jun 20 2025
NASDAQ.COM
Canaccord Genuity Maintains Buy on Bioventus, Maintains $15 Price Target
Mar 17 2025
Benzinga
Medical Device Firm Bioventus Stock Jumps On Upbeat 2025 Outlook, Cuts Debt By $48 Million
Mar 11 2025
Benzinga
Korn Ferry Posts Better-Than-Expected Earnings, Joins Bioventus, Endeavour Silver, Vail Resorts And Other Big Stocks Moving Higher On Tuesday
Mar 11 2025
Benzinga
Bioventus reports Q4 non-GAAP EPS 15c, consensus 8c
Mar 11 2025
Business Insider
Bioventus sees FY25 revenue $560M-$570M, consensus $554.78M
Mar 11 2025
Business Insider
BIOVENTUS Earnings Preview: Recent $BVS Insider Trading, Hedge Fund Activity, and More
Mar 04 2025
NASDAQ.COM
Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025
Feb 28 2025
Newsfilter
Insider Sale: SVP & CFO of $BVS Sells 6,498 Shares
Feb 21 2025
NASDAQ.COM
Show More News
